Viatris NEW Zealand

Viatris New Zealand is a pharmaceutical importer and distributor operating within New Zealand's healthcare sector. As a subsidiary of Viatris Inc., a global healthcare company formed in 2020 through the merger of Mylan and Upjohn (a legacy division of Pfizer), Viatris New Zealand plays a pivotal role in ensuring the availability of high-quality, trusted medicines to the New Zealand market. (viatris.nz)

Headquartered in Auckland, Viatris New Zealand employs approximately 50 individuals from diverse backgrounds, including Asia, the Pacific, and Brazil. This diverse workforce underscores the company's commitment to leveraging global expertise to meet local healthcare needs. (viatrisconnect.co.nz) Viatris New Zealand's portfolio encompasses a broad range of therapeutic areas, with over 500 registered products, reflecting its significant presence in the country's pharmaceutical distribution landscape. (viatris.nz)

Viatris New Zealand's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across the country. While specific warehouse locations are not publicly disclosed, the company operates a robust supply chain capable of delivering over one million units directly through its warehouse every month. (viatris.nz) This capacity indicates a well-established logistics framework that supports nationwide coverage. Additionally, Viatris New Zealand's affiliation with Viatris Inc., which has a global manufacturing network, including facilities in Australia, enhances its ability to source and distribute a diverse range of medicines. (viatrisconnect.co.nz)

In New Zealand's pharmaceutical supply chain, Viatris New Zealand functions primarily as a wholesaler and distributor. The company imports a diverse array of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from various international suppliers. This role is crucial in bridging the gap between global manufacturers and local healthcare providers, ensuring that patients have access to a wide range of medications. Viatris New Zealand's operations are integral to the country's healthcare infrastructure, facilitating the availability of essential medicines across multiple therapeutic categories.

Viatris New Zealand's sourcing strategy exhibits a high degree of concentration, with a significant majority of its pharmaceutical imports originating from a single supplier, MEDREICH LIMITED. This supplier accounts for $4.6 million in imports across 200 shipments, representing 98.6% of the total import value. Such a concentrated sourcing approach can offer benefits like streamlined logistics and potentially favorable pricing. However, it also introduces risks associated with supplier dependency, including potential disruptions due to geopolitical issues, regulatory changes, or operational challenges faced by the supplier. The limited number of suppliers (two) and the dominance of MEDREICH LIMITED suggest that Viatris New Zealand's supply chain may be vulnerable to single-source risks.

The resilience of Viatris New Zealand's supply chain is closely tied to its reliance on MEDREICH LIMITED for the majority of its pharmaceutical imports. The absence of additional backup suppliers for key products indicates a potential vulnerability in the event of supply disruptions. The diversity of formulations imported (136 unique formulations) suggests a broad product range; however, the heavy reliance on a single supplier for these products may limit the company's ability to quickly adapt to supply chain challenges. To enhance resilience, Viatris New Zealand could consider diversifying its supplier base and establishing relationships with multiple suppliers to mitigate risks associated with single-source dependency.

Viatris New Zealand's concentrated sourcing pattern positions it to leverage economies of scale and maintain strong supplier relationships. However, this strategy also exposes the company to risks associated with supplier dependency, which could impact its ability to respond to market fluctuations or supply chain disruptions. For Indian exporters, this presents an opportunity to diversify their customer base by offering alternative sources of supply, potentially reducing the risks associated with Viatris New Zealand's current single-source dependency. By providing reliable and consistent supply options, Indian exporters can position themselves as valuable partners in Viatris New Zealand's supply chain, enhancing their competitiveness in the New Zealand market.

In New Zealand, the Medicines and Medical Devices Safety Authority (Medsafe) is the primary regulatory body responsible for the regulation of therapeutic products, including pharmaceuticals. Medsafe operates under the Medicines Act 1981 and the Misuse of Drugs Act 1975, which govern the importation, manufacture, and distribution of medicines within the country. The regulatory framework ensures that all medicines meet safety, efficacy, and quality standards before they are approved for use in New Zealand. For Indian pharmaceutical companies seeking to export to New Zealand, obtaining marketing authorization from Medsafe is a critical step in the regulatory process.

Import licensing in New Zealand is managed by Medsafe, which requires that all imported medicines be accompanied by appropriate documentation, including a Certificate of Pharmaceutical Product (CPP) issued by the regulatory authority of the exporting country. This certificate attests to the product's compliance with the regulatory standards of the exporting country. Good Manufacturing Practice (GMP) certification is also essential; New Zealand recognizes GMP certifications from authorities such as the European Union (EU GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian pharmaceutical manufacturers seeking to export to New Zealand must ensure that their facilities are GMP-compliant and that their products are accompanied by the necessary import licenses and certifications.

Imported pharmaceutical products in New Zealand must undergo batch testing to confirm their quality, safety, and efficacy. Stability studies are required to ensure that products maintain their intended quality throughout their shelf life. Labeling requirements include the use of English language, with specific information such as the product name, active ingredients, dosage form, strength, batch number, expiry date, storage conditions, and the name and address of the manufacturer or distributor. Serialization mandates may apply to facilitate traceability and prevent counterfeit products; however, specific serialization requirements should be verified with Medsafe. Indian exporters must adhere to these quality and labeling standards to ensure compliance with New Zealand regulations.

Between 2024 and 2026, New Zealand's regulatory landscape for pharmaceutical imports has seen several developments. Medsafe has updated its guidelines to enhance the safety and efficacy of imported medicines, including stricter requirements for GMP certification and more detailed labeling standards. Additionally, there has been an increased emphasis on pharmacovigilance, with mandatory reporting of adverse drug reactions and a more rigorous assessment of clinical trial data. These changes aim to improve patient safety and ensure that imported medicines meet the highest standards of quality. Indian pharmaceutical companies exporting to New Zealand should stay informed about these regulatory updates to maintain compliance and ensure uninterrupted market access.

Viatris New Zealand's product strategy focuses on importing a diverse range of pharmaceutical formulations across multiple therapeutic categories, including antibiotics, analgesics, antipyretics, and gastrointestinal medications. This approach aligns with the company's mission to provide high-quality, trusted medicines to New Zealanders, addressing a broad spectrum of healthcare needs. The market demand for these products is driven by the prevalence of various health conditions in the population, necessitating a steady supply of effective treatments. By importing a wide array of products, Viatris New Zealand ensures that healthcare providers have access to essential medications, thereby supporting better health outcomes for patients.

Viatris New Zealand's sourcing strategy emphasizes the importation of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from international suppliers. This approach allows the company to offer a comprehensive product portfolio without the complexities associated with manufacturing raw active pharmaceutical ingredients (APIs). India plays a significant role in Viatris New Zealand's procurement strategy, serving as a key source of high-quality, cost-effective finished formulations. By leveraging India's manufacturing capabilities, Viatris New Zealand can provide a diverse range of medicines to meet the needs of the New Zealand market.

Viatris New Zealand serves a broad segment of the New Zealand pharmaceutical market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's extensive product portfolio and efficient distribution network enable it to meet the diverse needs of healthcare providers and patients across the country. By offering a wide range of high-quality medicines, Viatris New Zealand positions itself as a key player in the pharmaceutical supply chain, contributing to the overall health and well-being of the New Zealand population.

There is a realistic opportunity for new Indian suppliers to enter Viatris New Zealand's supply chain. The company's current sourcing pattern, characterized by a high degree of concentration with a single supplier, indicates potential gaps that new suppliers can fill. By offering reliable and consistent supply options, Indian exporters can position themselves as valuable partners, enhancing their competitiveness in the New Zealand market. To capitalize on this opportunity, Indian suppliers should ensure compliance with New Zealand's regulatory requirements, including GMP certification and appropriate labeling standards.

Indian exporters seeking to supply Viatris New Zealand must ensure that their